CD160 and cancer: Our study revealed that CREB3L1 expression was distinctly correlated with multiple immuneinhibitors genes, such as KDR, PVRL2, CD160, and CD96, and immunostimulators genes, such as NT5E, TNFRSF14, CD28, and CXCR4, and chemokines including CX3CL1, CXCL9, CCL15, and CXCL5 in multiple cancer types, suggesting the interactions between CREB3L1 and immune-related biomarkers expression in pan-cancer.